Search Results - Chandan K. Sen

Chandan K. Sen

Chandan K. Sen is an Indian-American scientist who is a globally recognized leader in regenerative medicine and wound care innovation, renowned for groundbreaking scientific discoveries and pioneering technologies that are reshaping the science of healing and advancing patient care. He is currently the Director of the McGowan Institute for Regenerative Medicine of the University of Pittsburgh. He is the Bartley P Griffith MD FACS FRCS Chair of Regenerative Medicine and tenured Professor of Surgery who also serves as the Chief Scientific Officer of wound care services of the University of Pittsburgh Medical Center health system. At the University of Pittsburgh, Professor Sen serves as Associate Vice Chancellor for Life Sciences Innovation and Commercialization. Dr. Sen is the current vice-chair and chair-elect of the National Institute of Health's Diabetic Foot Consortium.

Founded in 1992, [https://mirm-pitt.net/ McGowan Institute for Regenerative Medicine] was initially established as the McGowan Center for Artificial Organ Development. Professor Sen moved with a large team of scientists from Indiana to Pittsburgh in July 2023. During 2018-2023, Professor Sen served as an Indiana University Distinguished Professor. At Indiana University, Sen directed the Indiana Center for Regenerative Medicine and Engineering (ICRME) and held the J. Stanley Battersby Chair and Distinguished Professor of Surgery. He also served as the Associate Dean of Research as well as Associate Vice President of Research. In 2020, he was awarded the Bicentennial Medal by the University President's Office.

In 2021, Sen was elected Fellow to the National Academy of Inventors. Currently, he serves as Editor-in-Chief of ''[https://home.liebertpub.com/publications/antioxidants-and-redox-signaling/4 Antioxidants & Redox Signaling]'' as well as of ''[https://home.liebertpub.com/publications/advances-in-wound-care/605 Advances in Wound Care]''. Sen is known for his co-invention of the tissue nanotransfection technology for in vivo tissue reprogramming. His team identified [https://www.technologynetworks.com/cell-science/news/new-type-of-cell-involved-in-blood-vessel-creation-identified-370742 the vasculogenic fibroblasts] in humans. His work has included the study of the electroceutical management of infection, and tocotrienol form on natural vitamin E. Sen served as the primary principal investigator of the NIH Diabetic Foot Consortium TEWL study. The study called for revision of FDA definition of wound closure endpoint underscoring the need to include the requirement of restoration of barrier function of the skin at the site of closure. Wound that closed with deficient barrier function, characterized by high transepidermal water loss (TEWL), were more likely to recur. Sen has an H-index of 119. Provided by Wikipedia